tion improved, although he continued to have intermittent bouts of left upper limb myoclonic jerking. 4 He was stable until 2002 when he had several Klebsiella pneumoniae bacteremias. Frequent complex partial seizures (CPSs) developed, and EPC returned with continuous myoclonic jerking of the left upper limb and frequent, painful, dystonic, flexor spasms of the left fingers, wrist, and elbow, which sometimes spread to the shoulder. Although the CPS remitted with IV antibiotics and increasing his AED regimen (topiramate, 800 mg/d; phenytoin, 425 mg/d; levetiracetam, 3 g/d; and vigabatrin, 2 g/d), his involuntary movements persisted. Clonazepam (20 mg/d), IV midazolam boluses, and increasing prednisolone (1.5 mg/kg/d) and IV immunoglobulin (hIVIg; 2 g/kg fortnightly) doses had no effect. There was progressive atrophy of the remaining right cerebral hemisphere, caudate nucleus, and thalamus on serial brain MRI scans since 1993 (figure). However, there was no evidence of reactivation of brain inflammation on either the MRI scans or serial CSF analysis.
We tried freehand injections of BTX-A (Dysport, Ipsen, UK; total dose, 1000 mouse units Discussion. Repeated BTX-A injections were an effective treatment for our patient's late-onset, limb dystonia and continuous myoclonic jerking. Changes in the ipsilateral basal ganglia in association with cerebral hemisphere abnormalities are common in patients with RS and usually appear early in the course of the syndrome. In one serial MRI study, eight of eight patients with RS had atrophy of the head of the caudate nucleus at 4 months after onset of symptoms. 1 In another patient, atrophy of the right caudate, globus pallidus, and putamen and mild increased T2-weighted signal in the right striatum were the only MRI brain scan findings at presentation. 5 However, no additional EPCassociated involuntary movements were described in any of these patients, and reports of hyperkinetic movements other than myoclonus are rare in EPC associated with RS.
2 When these movements occur, they start typically at the onset or early in the course of the syndrome.
2 By contrast, our patient's involuntary movements started 14 years after the clinical onset of RS when there was established caudate atrophy. Human IVIg improved athetosis, dystonia, and EPC in one woman with RS, although the response was short lasting. 2 Increasing the doses of prednisolone and hIVIg had no effect on our patient's involuntary movements.
Our patient's repeated response to BTX-A contrasts with the reports of its ineffectiveness in two patients with EPC and in two children with RS and EPC. 6, 7 These previous findings suggest that uncomplicated EPC may be resistant to this therapy. However, it can be difficult clinically to distinguish the recurrent, simple focal motor seizures of EPC from the other hyperkinetic movements, especially myoclonus, occurring in patients with established RS.
We propose that BTX-A can be a useful, long-term therapy for involuntary, hyperkinetic movements in RS and that it should be considered especially for those patients with late-onset, focal movements that do not respond to conventional AED treatment or immunotherapy.
